keyword
MENU ▼
Read by QxMD icon Read
search

oxybutynin

keyword
https://www.readbyqxmd.com/read/29345103/incidence-of-common-cancers-in-users-of-antimuscarinic-medications-for-overactive-bladder-a-danish-nationwide-cohort-study
#1
Jesper Hallas, Andrea V Margulis, Anton Pottegård, Nina Sahlertz Kristiansen, Willem Jan Atsma, Kwame Appenteng, Stefan de Vogel, James A Kaye, Susana Perez-Gutthann, Alejandro Arana
The purpose of this study was to estimate the incidence rate (IR) of 10 common cancers in new users of antimuscarinic overactive bladder (OAB) medications. We conducted a cohort study using data recorded in Danish registers for patients newly exposed to the OAB drugs darifenacin, fesoterodine, oxybutynin, solifenacin, tolterodine or trospium in years 2004-2012, aged ≥18 years and without cancer before treatment initiation. We estimated IRs for each study cancer (bladder, breast, colorectal, lung, melanoma, non-Hodgkin lymphoma, pancreas, prostate, renal and uterine), standardised by age and sex and explored IR trends over time since treatment initiation...
January 17, 2018: Basic & Clinical Pharmacology & Toxicology
https://www.readbyqxmd.com/read/29334132/oxybutynin-3-gel-for-the-treatment-of-primary-focal-hyperhidrosis-in-adolescents-and-young-adults
#2
Nicholas V Nguyen, Jane Gralla, James Abbott, Anna L Bruckner
BACKGROUND/OBJECTIVES: There are no reliably effective, well-tolerated topical agents for the treatment of hyperhidrosis. We sought to evaluate the efficacy and tolerability of oxybutynin 3% gel in adolescents and young adults with primary focal hyperhidrosis. METHODS: Patients with severe axillary hyperhidrosis were treated with topical oxybutynin 3% gel for 4 weeks. Response to treatment was assessed by calculating change in Hyperhidrosis Disease Severity Score from baseline to weeks 1 and 4...
January 15, 2018: Pediatric Dermatology
https://www.readbyqxmd.com/read/29319477/publicly-funded-overactive-bladder-drug-treatment-patterns-in-ontario-over-15-years-an-ecologic-study
#3
Mina Tadrous, Dean Elterman, Wayne Khuu, Muhammad M Mamdani, David N Juurlink, Tara Gomes
INTRODUCTION: Medication is an important option for patients with overactive bladder (OAB), with four different drugs approved over the last 10 years including the first non-anticholinergic treatment, mirabegron. We set out to describe the number and rate of users of medication for the management of OAB over the last 15 years among residents of Ontario, Canada covered by the public drug programs. METHODS: We conducted a population-based, repeated cross-sectional study examining quarterly publically-funded prescription claims for OAB medications from January 2000 to June 2016 in Ontario, Canada...
December 22, 2017: Canadian Urological Association Journal, Journal de L'Association des Urologues du Canada
https://www.readbyqxmd.com/read/29287033/impact-of-new-medications-and-4-generic-programs-on-overactive-bladder-treatment-among-older-adults-in-the-united-states-2000-2015
#4
Alan C Kinlaw, Michele Jonsson Funk, Mitchell M Conover, Virginia Pate, Alayne D Markland, Jennifer M Wu
BACKGROUND: Despite several new medications being Food and Drug Administration-approved for overactive bladder (OAB) and new prescription drug payment programs, there are limited population-based data regarding OAB medication use among older adults. OBJECTIVES: To examine: (1) impacts of new medications and $4 generic programs on time trends for OAB-related medication dispensing for older adults in the United States; (2) differences by age and sex; and (3) temporal changes in OAB-related medication payments...
December 28, 2017: Medical Care
https://www.readbyqxmd.com/read/29220103/survival-study-of-treatment-adherence-by-patients-given-oral-oxibutynin-for-hyperhidrosis
#5
José Francisco Millán-Cayetano, Javier Del Boz, Pablo García-Montero, Cristina García-Harana, Francisco Rivas Ruiz, Magdalena de Troya-Martín
INTRODUCTION: In recent years, increasing use has been made of oral anticholinergics such as oxybutynin for the management of hyperhidrosis. The primary aim of this study is to determine the variables associated with adherence to this treatment, and secondarily to obtain data on its effectiveness, safety and adverse effects. MATERIAL AND METHODS: Prospective study of patients with hyperhidrosis, at any location, receiving treatment with oral oxybutynin in the period 2007-2016...
December 8, 2017: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/29193937/-tamsulosin-oxybutynin-or-their-combination-in-the-treatment-of-ureteral-stent-related-symptoms
#6
Efraín Maldonado-Alcaraz, Jorge Moreno-Palacios, Virgilio A López-Sámano, Claudia Landa-Salas, León O Torres-Mercado, Carlos GarcíaCruz
BACKGROUND: The aim of this paper is to compare the efficacy of tamsulosin, oxybutynin or their combination for the treatment of symptoms related to double J stent (DJS). METHODS: Randomized clinical non-blinded trial with three arms (tamsulosin, oxybutynin or combination) to assess the improvement of ureteral related symptoms with DJS with the questionnaire of Ureteral Stent Symptom Questionnaire (USSQ) and the adverse effects of treatment. Evaluations were made at 7 and 21 days after the placement of DJS...
September 2017: Revista Médica del Instituto Mexicano del Seguro Social
https://www.readbyqxmd.com/read/29140559/comparative-efficacy-and-tolerability-of-solifenacin-5%C3%A2-mg-day-versus-other-oral-antimuscarinic-agents-in-overactive-bladder-a-systematic-literature-review-and-network-meta-analysis
#7
Jameel Nazir, Con Kelleher, Samuel Aballéa, Khaled Maman, Zalmai Hakimi, Colette Mankowski, Isaac Odeyemi
AIMS: To compare efficacy and tolerability of solifenacin 5 mg/day versus other oral antimuscarinic agents for the treatment of overactive bladder (OAB). METHODS: Literature searches of MEDLINE, Embase, and the Cochrane Library were undertaken to identify randomized controlled trials in OAB (2000-2015) for antimuscarinic agents. A network meta-analysis (NMA) was performed to estimate efficacy and tolerability outcomes for solifenacin 5 mg/day relative to other antimuscarinics...
November 15, 2017: Neurourology and Urodynamics
https://www.readbyqxmd.com/read/29134621/replication-of-mini-sentinel-study-assessing-mirabegron-and-cardiovascular-risk-in-non-mini-sentinel-databases
#8
Jason C Simeone, Beth L Nordstrom, Kwame Appenteng, Samuel Huse, Milbhor D'Silva
BACKGROUND: In 2014, the US Food and Drug Administration (FDA) initiated a prospective routine surveillance using the Mini-Sentinel (M-S) program to assess potential signals of acute myocardial infarction (AMI) and stroke with use of mirabegron, indicated for the treatment of overactive bladder (OAB), compared with oxybutynin. PURPOSE: To replicate the FDA M-S analysis of mirabegron using datasets that did not contribute to the M-S program. METHODS: IMS PharMetrics Plus and Truven MarketScan claims data from 2012-2015 were converted to the M-S Common Data Model...
November 13, 2017: Drugs—Real World Outcomes
https://www.readbyqxmd.com/read/29134254/comparison-of-cardiovascular-events-among-treatments-for-overactive-bladder-a-danish-nationwide-cohort-study
#9
Andrea V Margulis, Jesper Hallas, Anton Pottegård, Nina Sahlertz Kristiansen, Willem Jan Atsma, Billy Franks, Milbhor D'Silva, Cristina Varas-Lorenzo, Susana Perez-Gutthann, Alejandro Arana
PURPOSE: The purpose of this study is to explore the cardiovascular safety of antimuscarinic drugs to treat overactive bladder (OAB) in Denmark. METHODS: This was a cohort study using data recorded in Danish registries from patients newly exposed to darifenacin, fesoterodine, oxybutynin, solifenacin, tolterodine, or trospium in 2004-2012. We estimated crude and standardized incidence rates (IRs) for acute myocardial infarction (AMI); stroke; cardiovascular mortality; major adverse cardiac events (MACE, a combined endpoint of the previous three outcomes); and all-cause death for the individual and combined drugs...
November 13, 2017: European Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/28906080/persistence-and-adherence-with-mirabegron-vs-antimuscarinics-in-overactive-bladder-retrospective-analysis-of-a-uk-general-practice-prescription-database
#10
Adrian S Wagg, Steve Foley, John Peters, Jameel Nazir, Leanne Kool-Houweling, Ludmila Scrine
INTRODUCTION AND OBJECTIVES: Persistence with antimuscarinic (AM) drugs prescribed for overactive bladder (OAB) is poor. This study aimed to compare persistence and adherence with the beta-3-adrenoceptor agonist mirabegron (MIR) vs AMs over 12 months. PATIENTS AND METHODS: This retrospective cohort analysis included patients aged ≥18 years who were prescribed MIR, or any AM. A 12-month look-back was used to assess inclusion eligibility. The primary end-point was persistence, defined as time to first discontinuation of index drug, during 1 year follow-up...
October 2017: International Journal of Clinical Practice
https://www.readbyqxmd.com/read/28747995/assessment-of-inhibitory-effects-on-major-human-cytochrome-p450-enzymes-by-spasmolytics-used-in-the-treatment-of-overactive-bladder-syndrome
#11
Dominik Dahlinger, Sevinc Aslan, Markus Pietsch, Sebastian Frechen, Uwe Fuhr
BACKGROUND: The objective of this study was to examine the inhibitory potential of darifenacin, fesoterodine, oxybutynin, propiverine, solifenacin, tolterodine and trospium chloride on the seven major human cytochrome P450 enzymes (CYP) by using a standardized and validated seven-in-one cytochrome P450 cocktail inhibition assay. METHODS: An in vitro cocktail of seven highly selective probe substrates was incubated with human liver microsomes and varying concentrations of the seven test compounds...
July 2017: Therapeutic Advances in Urology
https://www.readbyqxmd.com/read/28743177/traditional-suburethral-sling-operations-for-urinary-incontinence-in-women
#12
REVIEW
Haroon Rehman, Carlos A Bezerra, Homero Bruschini, June D Cody, Patricia Aluko
BACKGROUND: Stress urinary incontinence constitutes a significant health and economic burden to society. Traditional suburethral slings are one of the surgical operations used to treat women with symptoms of stress urinary incontinence. OBJECTIVES: To determine the effects of traditional suburethral slings on stress or mixed incontinence in comparison with other management options. SEARCH METHODS: We searched the Cochrane Incontinence Group Specialised Register (searched 3 June 2010) and the reference lists of relevant articles...
July 26, 2017: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/28714784/the-management-of-paediatric-neurogenic-bladder-an-approach-in-a-resource-poor-setting
#13
Patrick Opoku Manu Maison, John Lazarus
BACKGROUND: If untreated, paediatric neurogenic bladder can cause renal failure and urinary incontinence. It is usually caused by neural tube defects such as myelomeningocele. Children with a neurogenic bladder should be monitored from birth and management should aim to preserve renal function and achieve social continence. This article outlines the management options appropriate for these children in resource-poor settings. ASSESSMENT: In most low- and middle-income countries, a general lack of awareness of the neurological effects on the urinary tract results in late presentation, usually with urological complications even when spina bifida is diagnosed early...
July 17, 2017: Paediatrics and International Child Health
https://www.readbyqxmd.com/read/28678009/-tolerability-persistence-and-satisfaction-retrospective-cohort-study-in-patients-with-overactive-bladder-syndrome-treated-with-transdermal-oxybutynin-under-standard-clinical-practice-oscar-study
#14
Raúl Vozmediano-Chicharro, Pedro Blasco Hernández, Blanca Madurga-Patuel
OBJECTIVES: To determine the tolerability, persistenceand satisfaction of patients with overactive bladder syndrome (OAB) treated with transdermal oxybutynin (OXY-TDS). METHODS: Observational, retrospective, multicenter study, in patients with OAB who had started treatment with OXY-TDS at least 12 months before their inclusion. Tolerability was evaluated by number, severity criteria, resolution type of adverse reactions, and cognitive function with Mini-Mental State Examination (MMSE), at 1 year of treatment...
July 2017: Archivos Españoles de Urología
https://www.readbyqxmd.com/read/28654131/topical-oxybutynin-10-gel-for-the-treatment-of-primary-focal-hyperhidrosis-a-randomized-double-blind-placebo-controlled-split-area-study
#15
Ofir Artzi, Christophoros Loizides, Eyal Zur, Eli Sprecher
Limited efficacy, costs, side-effects and complications are issues of concern for most current therapeutic modalities for focal hyperhidrosis. This study evaluated the efficacy of topical oxybutynin 10% gel in treating 61 patients with primary focal hyperhidrosis. The gel was applied to the right or left axilla, palms or soles vs. a placebo compound to the contralateral side for 30 days. A blinded visual grading of the change in starch-iodine tests was performed by 2 non-involved physicians. The Hyperhidrosis Disease Severity Scale (HDSS) and Dermatology Life Quality Index (DLQI) questionnaires were administered before and after treatment...
October 2, 2017: Acta Dermato-venereologica
https://www.readbyqxmd.com/read/28608746/new-insights-in-the-metabolism-of-oxybutynin-evidence-of-n-oxidation-of-propargylamine-moiety-and-rearrangement-to-enaminoketone
#16
Silvio Aprile, Rossana Canavesi, Rosanna Matucci, Cristina Bellucci, Erika Del Grosso, Giorgio Grosa
1. Oxybutynin hydrochloride is an antimuscarinic agent prescribed to patients with an overactive bladder and symptoms of urinary urge incontinence. Oxybutynin undergoes pre-systemic metabolism, and the N-desethyloxybutynin (Oxy-DE), is reported to have similar anticholinergic effects. 2. We revisited the oxidative metabolic fate of oxybutynin by liquid chromatography tandem mass spectrometry analysis of incubations with rat and human liver fractions, and by measuring plasma and urine samples collected after oral administration of oxybutynin in rats...
June 13, 2017: Xenobiotica; the Fate of Foreign Compounds in Biological Systems
https://www.readbyqxmd.com/read/28574523/neuropathic-pain-treatment-provides-unexpected-benefit
#17
Adam D Keesling, Meg Wilson, Robert Wilkins
A 57-year-old African American woman was being treated at our clinic for neurogenic urinary incontinence (UI). The UI, which occurred day and night, began 2 years earlier following a laminectomy of vertebrae C3 to C6 with spinal fusion of C3 to C7 for cervical spinal stenosis. The UI persisted despite physical therapy and trials of oxybutynin and imipramine. Since the surgery, the patient had also been experiencing chronic (debilitating) neuropathic pain in both legs, and the sensation of incomplete bladder emptying...
June 2017: Journal of Family Practice
https://www.readbyqxmd.com/read/28544353/chiral-separation-of-12-pairs-of-enantiomers-by-capillary-electrophoresis-using-heptakis-2-3-diacetyl-6-sulfato-%C3%AE-cyclodextrin-as-the-chiral-selector-and-the-elucidation-of-the-chiral-recognition-mechanism-by-computational-methods
#18
Yaqi Yao, Peilu Song, Xiaoli Wen, Miaoduo Deng, Jian Wang, Xingjie Guo
Chiral separation of 12 pairs of basic analyte enantiomers including oxybutynin, bambuterol, tradinterol, clenbuterol, clorprenaline, terbutaline, tulobuterol, citalopram, phencynonate, fexofenadine, salbutamol and penehyclidine was conducted by capillary electrophoresis using a single-isomer anionic β-cyclodextrin derivative, heptakis-(2,3-diacetyl-6-sulfato)-β-cyclodextrin as the chiral selector. Parameters influencing separation were studied, including background electrolyte pH, heptakis-(2,3-diacetyl-6-sulfato)-β-cyclodextrin concentration, buffer concentration and separation voltage...
May 24, 2017: Journal of Separation Science
https://www.readbyqxmd.com/read/28538882/oxybutynin-as-an-alternative-treatment-for-hyperhidrosis
#19
REVIEW
Sergio Delort, Evaldo Marchi, Marcos Antônio Corrêa
Hyperhidrosis is the excessive production of sweating, which can be primary and focal or secondary to various pathologies. The exact cause of primary focal hyperhidrosis is still unknown, although a genetic basis is recognized, and its prevalence varies from 1% to 2.8%. The most affected sites are the armpits, palms, soles and face. It causes much discomfort, affects the quality of life, and is estimated to be undervalued by health professionals. Many treatment options are proposed, both clinical and surgical...
March 2017: Anais Brasileiros de Dermatologia
https://www.readbyqxmd.com/read/28522061/oral-oxybutynin-for-multiple-eccrine-hidrocystomas
#20
Burak Tekin, Ayşe Serap Karadag, Mahmut Can Koska
No abstract text is available yet for this article.
June 2017: Journal of the American Academy of Dermatology
keyword
keyword
110797
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"